IP Library › Granted Patent US 7,957,909
Granted Patent B2
US 7,957,909 · App. 11/159,376 · Granted Jun 7, 2011

Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles

Assignee: Source Precision Medicine, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,957,909
App. No.
11/159,376
Granted
Jun 7, 2011
Kind
B2
Abstract

Gene expression data, in particular gene expression profiles, are created and used in the identification, monitoring and treatment of disease and characterization of biological conditions. Profile data sets are derived from subject samples and include quantitative substantially repeatable measures of a distinct amount of RNA or protein constituent in a panel selected to enable evaluation of a biological condition. Such profile data sets may be used to provide an index indicative of the biological state of a subject, which may be compared to a normative value of the index determined with respect to a relevant population of subjects.

Claims (8)

1. A method, for evaluating a biological condition of a target population of cells affected by an agent based on a sample from the population of cells, the sample providing a source of RNAs, the method comprising:

using amplification to determine a quantitative measure of the amount of RNA of at least two constituents from any one of Tables 1 through 12 from the sample of the target population of cells, where a panel of constituents is selected so that measurement of the constituents enables measurement of the biological condition and wherein the measures of all constituents in the panel form a first profile data set;

using amplification to determine a quantitative measure of the amount of RNA of all constituents in said panel wherein measures of all constituents in the panel are from a relevant population of target cells and form a normative baseline profile data set, wherein the measures for each constituent are performed under measurement conditions that are (i) within a degree of repeatability of better than ten percent and (ii) the efficiencies of amplification for all constituents differ by less than 10 percent; and

producing a calibrated profile data set for said panel, wherein each member of the calibrated profile data set is a function of a corresponding member of the first profile data set and the corresponding member of a baseline profile data set; and

wherein the calibrated profile data set provides a measure of the biological condition of the target population of cells as affected by the agent.

2. A method according to claim 1 , wherein the relevant population of target cells is a population of cells from healthy subjects.

3. A method according to claim 1 , wherein the relevant population of target cells has in common a property that is at least one of age group, gender, ethnicity, geographic location, diet, medical disorder, clinical indicator, medication, physical activity, body mass, and environmental exposure.

4. A method according to claim 1 , wherein the panel includes at least two of the constituents of the Inflammation Gene Expression Panel of Table 1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2011
From: SOURCE PRECISION MEDICINE, INC. D/B/A SOURCE MDX
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 026238/0857 →
Continuity (10)
Continuation 10291225 · Nov 8, 2002
Continuation In Part 09821850 · Mar 29, 2001
Continuation In Part 09605581 · Jun 28, 2000
Provisional Application 60141542 · Jun 28, 1999
Provisional Application 60195522 · Apr 7, 2000
Provisional Application 60348213 · Nov 9, 2001
Provisional Application 60340881 · Dec 7, 2001
Provisional Application 60369633 · Apr 3, 2002
Provisional Application 60376997 · Apr 30, 2002
Related Publication 20050250148A1 · Nov 10, 2005